Weight | 1 lbs |
---|---|
Dimensions | 9 × 5 × 2 in |
host | mouse |
isotype | IgG1 |
clonality | monoclonal |
concentration | 1 mg/mL |
applications | ICC/IF, IHC, WB |
available sizes | 100 µg |
mouse anti-GFAP monoclonal antibody (2E1) 9024
$409.00
Antibody summary
- Mouse monoclonal to GFAP
- Suitable for: WB, ICC/IF, IHC
- Reacts with: human, mouse, rat
- Isotype: IgG2b
- 100 µg
mouse anti-GFAP monoclonal antibody (2E1) 9024
target relevance |
---|
Glial Fibrillary Acidic Protein (GFAP) is a crucial cell marker widely employed in neuroscience and neurobiology research. It is an intermediate filament protein primarily found in astrocytes, a type of glial cell in the central nervous system. GFAP serves as a reliable marker for identifying and characterizing astrocytes in various experimental models and tissues. Immunohistochemistry and immunofluorescence techniques using antibodies targeting GFAP enable researchers to visualize and quantify astrocytic populations, gaining insights into their distribution, morphology, and function in the brain. Moreover, GFAP antibodies are instrumental in studying astrocyte reactivity, a phenomenon occurring in response to brain injury or neurodegenerative diseases. As astrocytes play critical roles in neural development, neurotransmitter regulation, and maintenance of the blood-brain barrier, GFAP has proven indispensable in advancing our understanding of glial biology and its contribution to neurological disorders. Click for more on: cell markers and GFAP |
Protein names Glial fibrillary acidic protein (GFAP) |
Gene names GFAP,GFAP |
Protein family Intermediate filament family |
Mass 49880Da |
Function GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. |
Subellular location Cytoplasm Note=Associated with intermediate filaments. |
Tissues Expressed in cells lacking fibronectin. |
Structure Interacts with SYNM. ; [Isoform 2]: Interacts with PSEN1 (via N-terminus). |
Post-translational modification Phosphorylated by PKN1. |
Involvement in disease Alexander disease (ALXDRD) [MIM:203450]: A rare disorder of the central nervous system. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death within the first decade. Infants with Alexander disease develop a leukodystrophy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course. Histologically, Alexander disease is characterized by Rosenthal fibers, homogeneous eosinophilic inclusions in astrocytes. Note=The disease is caused by variants affecting the gene represented in this entry. |
Target Relevance information above includes information from UniProt accession: P14136 |
The UniProt Consortium |
Data
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.There are 30 publications in our database for this antibody or clone. Here are the latest 5, for more click below.
pmid | title | authors | citation |
---|---|---|---|
37759938 | Neuroimmune Support of Neuronal Regeneration and Neuroplasticity following Cerebral Ischemia in Juvenile Mice | Marquez-Ortiz RA, Tesic V, Hernandez DR, Akhter B, Aich N, Boudreaux PM, Clemons GA, Wu CY, Lin HW, Rodgers KM. | Brain Sci. 2023 Sep 17;13(9):1337. doi: 10.3390/brainsci13091337. |
37667307 | Metal-organic framework materials promote neural differentiation of dental pulp stem cells in spinal cord injury | Zhou H, Jing S, Xiong W, Zhu Y, Duan X, Li R, Peng Y, Kumeria T, He Y, Ye Q. | J Nanobiotechnology. 2023 Sep 4;21(1):316. doi: 10.1186/s12951-023-02001-2. |
37605262 | Inhibition of acid sphingomyelinase reduces reactive astrocyte secretion of mitotoxic extracellular vesicles and improves Alzheimer's disease pathology in the 5xFAD mouse | Crivelli SM, Quadri Z, Vekaria HJ, Zhu Z, Tripathi P, Elsherbini A, Zhang L, Sullivan PG, Bieberich E. | Acta Neuropathol Commun. 2023 Aug 21;11(1):135. doi: 10.1186/s40478-023-01633-7. |
37587766 | USP25 Inhibits Neuroinflammatory Responses After Cerebral Ischemic Stroke by Deubiquitinating TAB2 | Li Z, Liu B, Lambertsen KL, Clausen BH, Zhu Z, Du X, Xu Y, Poulsen FR, Halle B, Bonde C, Chen M, Wang X, Schlüter D, Huang J, Waisman A, Song W, Wang X. | Adv Sci (Weinh). 2023 Oct;10(28):e2301641. doi: 10.1002/advs.202301641. Epub 2023 Aug 16. |
37513944 | EYE-503: A Novel Retinoic Acid Drug for Treating Retinal Neurodegeneration | Liu S, Ji Y, Li H, Ren L, Zhu J, Yang T, Li X, Yao J, Cao X, Yan B. | Pharmaceuticals (Basel). 2023 Jul 20;16(7):1033. doi: 10.3390/ph16071033. |
Protocols
relevant to this product |
---|
Western blot IHC ICC |
Documents
# | |||
---|---|---|---|
Please enter your product and batch number here to retrieve - product datasheet, SDS, and QC information. |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.